Strengthening our leadership in lentiviral vectors for in vivo applications

In 2025, VIVEbiotech proudly celebrates 10 years of innovation and excellence in lentiviral vector manufacturing. Over the past decade, we’ve established ourselves as the only GMP CDMO in Europe exclusively dedicated to lentiviral vectors, becoming a global reference in in vivo applications for gene and cell therapy.

With 50+ international projects and 180+ batches manufactured —half of them in the past three years—, we support clients worldwide across all development stages thanks to our plug-and-play platform. Today, we actively support 10 in vivo projects, including 2 already in the clinic.

What sets us apart:
🔹 Full focus on lentiviral vectors
🔹 Advanced pseudotyping strategies and tropism optimization
🔹 Agile, tailored, and flexible service
🔹 Regulatory strength (EMA and FDA-compliant)
🔹 Full commitment to our clients’ programs

Thanks to this vision and collaboration, we’ve built a decade of leadership and continue driving forward impactful therapies.

Let’s move advanced therapies forward—together.